This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Chemed (CHE) Faces Macroeconomic Woes, Tough Competition
by Zacks Equity Research
Inflationary trend, increased logistics costs and higher employee-related expenses continue to hurt Chemed's (CHE) growth.
Vicarious Surgical (RBOT) to Broaden User Network With New Deal
by Zacks Equity Research
Vicarious Surgical's (RBOT) partnership with Intermountain Health is likely to help the company gain access to Intermountain Health's extensive network.
CVS Health's (CVS) New COVID-19 Vaccine Available at Its Stores
by Zacks Equity Research
CVS Health's (CVS) updated mRNA COVID-19 vaccine is now available at all its pharmacy locations.
Walgreens (WBA) Expands Primary Care Research With New Pact
by Zacks Equity Research
Walgreens (WBA) will reach more communities quickly and provide comprehensive, cost-effective care with the new collaboration.
SmileDirectClub (SDC) New Alliances Aid, Macro Woes Hurt
by Zacks Equity Research
SmileDirectClub (SDC) is focused on developing transformative innovations to serve the growing needs of the current customer base and expanded segments of higher-income demographics.
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of TAVR and a solid balance sheet.
Syneos Health (SYNH) Declares Strategic Partnership With Oracle
by Zacks Equity Research
Syneos Health (SYNH) announces an expanded collaboration with Oracle to accelerate patient recruitment capabilities.
Bruker (BRKR) Inks Fraport Framework Contract for ETD Systems
by Zacks Equity Research
Bruker's (BRKR) DE-tector flex system uses a non-radioactive ionization source and is approved by national regulatory bodies and ECAC.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) on improvement in testing volume across all its businesses.
Insulet (PODD) Expands Omnipod 5 Even As Macro Woes Linger
by Zacks Equity Research
Insulet's (PODD) international expansion efforts are aligned with its long-term growth profile.
QIAGEN's (QGEN) New API Streamlines Access to BKB Data
by Zacks Equity Research
QIAGEN (QGEN) introduces API to give easier access to the QIAGEN Biomedical Knowledge Base.
NanoString (NSTG) Grows in Translational Research With CRO Deals
by Zacks Equity Research
According to NanoString (NSTG), SMI's unique ability to interrogate both RNA and proteins at ultra-high plex with subcellular resolution has made it a one-of-a-kind tool.
Thermo Fisher (TMO) to Advance Clinical Research With New Pact
by Zacks Equity Research
Thermo Fisher's clinical research division will aid in increasing community health clinics' capacity to participate in clinical studies.
Alcon (ALC) Surgical Advances With New Data on AcrySof IQ Vivity
by Zacks Equity Research
Alcon's (ALC) Vivity Registry study data highlights the lens's versatility in treating a wide range of patients.
Align Technologies (ALGN) Brings New Upgrades for Oral Health
by Zacks Equity Research
Align Technologies (ALGN) introduces a series of software innovations to accelerate the digital practice transformation.
Globus Medical (GMED) Launches NuVasive's NSO in Global Market
by Zacks Equity Research
Globus Medical's (GMED) Precice Bone Transport is a less intrusive treatment that reduces complications for both the patient and the surgeon and is designed for various bone abnormalities.
National Vision (EYE) Gains From Store Opening Amid Macro Woes
by Zacks Equity Research
In terms of store expansion, National Vision (EYE) continues to see a sizable new opportunity with growth for the coming years.
Thermo Fisher (TMO) Adds New Platform to CTS Product Portfolio
by Zacks Equity Research
Thermo Fisher (TMO) launches the next-generation Gibco CTS Detachable Dynabeads platform.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR), backed by the performance of the CALID and NANO groups and strength in acquisitions.
Exact Sciences (EXAS) Gains From New Buyouts Amid Rising Costs
by Zacks Equity Research
Exact Sciences (EXAS) is improving customer experience by making it simpler to order Cologuard electronically and continue re-screening of patients every three years.
Align Technologies (ALGN) Set to Acquire Cubicure GmbH
by Zacks Equity Research
Align Technologies (ALGN) announces acquisition of direct 3D printing pioneer Cubicure GmbH, backed by years of successful collaboration.
Boston Scientific (BSX) WATCHMAN FLX Pro Gets FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) latest device features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS), backed by Cologuard growth and upbeat guidance.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on the RMS segment's continued growth and upbeat guidance.
Abbott (ABT) to Advance Diabetes Care With New Acquisition
by Zacks Equity Research
Abbott's (ABT) recent deal will enable it to create more interconnected solutions to improve the personalization and accuracy of diabetes control.